Compare INLF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLF | LUNG |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | China | United States |
| Employees | 156 | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7M | 57.9M |
| IPO Year | N/A | 2020 |
| Metric | INLF | LUNG |
|---|---|---|
| Price | $3.19 | $1.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 49.3K | ★ 297.1K |
| Earning Date | 03-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.24 | $1.13 |
| 52 Week High | $5.20 | $5.46 |
| Indicator | INLF | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 38.77 |
| Support Level | $0.40 | $1.13 |
| Resistance Level | $5.20 | $1.64 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 0.00 | 4.03 |
INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. Its portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.